Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study
2004-000506-52Phase 3Completed
- Sponsor
- Daiichi Sankyo
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), Microalbuminuria and cardiac morbidity comparing Olmetec 40 mg with Placebo (2 arms). Primary endpoint: Time to first occurrence of microalbuminuria. Started Oct 2004; status: completed.
02
Drugs
olmesartan
03
Conditions
type 2 diabetes mellitus (T2DM)Microalbuminuriacardiac morbidity
Beyond the preview
Go deeper on 2004-000506-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000506-52.